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Introduction
Vascular inflammation promotes the progression of
coronary artery disease; moreover, it triggers acute
coronary syndromes [13, 15]. Tissue factor (TF) is
regulated by a variety of inflammatory mediators
and initiates activation of coagulation. Consistent
with this observation, experimental evidence has
revealed an important contribution of TF to arterial
thrombosis, the key event in acute coronary syn-
dromes [28, 30, 31]. Clinical observations have in-
deed confirmed that cytokine concentrations high
enough to induce endothelial expression of TF are
reached at the culprit lesion of patients with acute
coronary syndrome [19].
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j Abstract Background The phytosterol guggulsterone is a potent anti-
inflammatory mediator with less side effects than classic steroids. This
study assesses the impact of guggulsterone on tissue factor (TF)
expression and thrombus formation. Methods and results Guggulsterone
inhibited TNF-a-induced endothelial TF protein expression and surface
activity in a concentration-dependent manner; in contrast, dexametha-
sone did not affect TNF-a-induced TF expression. Guggulsterone
enhanced endothelial tissue factor pathway inhibitor and impaired
plasminogen activator inhibitor-1 as well as vascular cell adhesion
molecule-1 protein. Real-time polymerase chain reaction revealed that
guggulsterone inhibited TNF-a-induced TF mRNA expression; moreover,
it impaired activation of the MAP kinases JNK and p38, while that of ERK
remained unaffected. In vivo, guggulsterone inhibited TF activity and
photochemical injury induced thrombotic occlusion of mouse carotid
artery. Guggulsterone also inhibited TF expression, proliferation, and
migration of vascular smooth muscle cells in a concentration-dependent
manner. Conclusions Guggulsterone inhibits TF expression in vascular
cells as well as thrombus formation in vivo; moreover, it impairs vascular
smooth muscle cell activation. Hence, this phytosterol offers novel
therapeutic options, in particular in inflammatory diseases associated
with an increased risk of thrombosis.
j Key words arterial thrombosis – photochemical injury –
phytosterol – tissue factor
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Guggulsterone [4,17(20)-pregnadiene-3,16-dione]
is a plant derived steroid isolated from the gum resin
of the tree Commiphora mukul, which has been
extensively used in Ayurvedic medicine to treat sev-
eral conditions associated with inflammation such as
hyperlipidemia, obesity, and arthritis [1, 14, 23, 34].
Guggulsterone indeed exerts strong anti-inflamma-
tory effects by suppressing the activation of the
transcription factor NF-kappa B in response to dif-
ferent agonists including tumor necrosis factor a
(TNF-a) [22]. In line with its anti-inflammatory
properties, previous studies revealed that guggulster-
one is able to impair LDL oxidation, thereby delaying
the progression of atherosclerosis [3, 37].
Since guggulsterone is an anti-inflammatory, well-
tolerated, natural drug, this study was designed to
investigate its impact on cytokine-induced TF expres-
sion as well as arterial thrombus formation in vivo.
Materials and methods
j Cell culture
Human aortic endothelial cells (HAECs; Clonetics,
Allschwil, Switzerland) and human aortic vascular
smooth muscle cells (VSMCs) were cultured as de-
scribed [24]. THP-1 cells (LGC Promochem, Mols-
heim, France) were kept in RPMI containing 10% fetal
calf serum (FCS). Adhering cells were grown to con-
fluence and rendered quiescent for 24 h before stim-
ulation with 5 ng/ml TNF-a (R&D, Minneapolis, MN).
Cells were pretreated with guggulsterone, dexameth-
asone (all from Sigma, Buchs, Switzerland), or GW-
4064 (Tocris Bioscience, Ellisville, MI) for 60 min
before stimulation. Cytotoxicity was assessed by a
colorimetric assay to detect lactate dehydrogenase
release (Roche, Basel, Switzerland) [25].
For proliferation, VSMCs were cultured for 24 h in
Dulbecco’s modified Eagle medium (DMEM) with
10% FCS. Cells were then serum withdrawn for 48 h
before stimulation with 10% FCS in the presence of
different guggulsterone concentrations. Media were
replaced daily, and cell number was determined after
3 days with a hemocytometer (Assisten, Sondheim,
Germany) [5]. For migration, VSMCs were cultured
for 24 h in DMEM with 10% FCS and then harvested
and resuspended (500,000 cells/ml) for analysis of
migration in response to platelet-derived growth
factor BB (10 ng/ml) in a modified Boyden chamber
system (NeuroProbe Inc, Gaithersburg, MD) [5].
j Western blot
Protein expression was determined by Western blot
analysis as described [26]. Antibodies against human
TF and tissue factor pathway inhibitor (TFPI; both
from American Diagnostica, Stamford, CT) were used
at 1:2,000 dilution. Antibodies against phosphorylated
p38 MAP kinase (p38), p44/42 MAP kinase (extra-
cellular signal-regulated kinase [ERK]), and c-Jun
NH2-terminal kinase (JNK; all from Cell Signaling,
Danvers, MA) were used at 1:1,000, 1:5,000, and
1:1,000 dilution, respectively. Antibodies against total
p38, ERK, and JNK (all from Cell Signaling) were used
at 1:3,000, 1:2,000, and 1:1,000 dilution, respectively.
Antibodies against vascular cell adhesion molecule-1
(VCAM-1; R&D) and plasminogen activator inhibitor-
1 (PAI-1; Santa Cruz) were applied at 1:2,000 and
1:4,000 dilution, respectively. Anti-goat glyceralde-
hyde-3-phosphate dehydrogenase antibody (GAPDH;
Chemicon, Temecula, CA) was applied to ensure
equal protein loading (1:20,000 dilution). Proteins
were detected with a horseradish peroxidase-linked
secondary antibody (Amersham).
j Real-time PCR
All real-time PCR experiments were performed in
triplicate using the SYBR Green JumpStart kit (Sigma)
in an MX3000P PCR cycler (Stratagene, Amsterdam,
The Netherlands). Each reaction (25 ll) contained
2 ll cDNA, 1 pmol of each primer, 0.25 ll of internal
reference dye, and 12.5 ll of JumpStart Taq ReadyMix
(containing buffer, dNTPs, stabilizers, SYBR Green,
Taq polymerase, and JumpStart Taq antibody). The
following primers were used: human tissue factor
(F3): sense primer: 5¢-TCCCCAGAGTTCACACCT-
TACC-3¢ (bases 508–529 of F3 cDNA; NCBI no. NM
001993), antisense primer: 5¢-TGACCACAAA-
TACCACAGCTCC-3¢ (bases 892–913 of F3 cDNA;
NCBI no. NM 001993); human L28: sense primer: 5¢-
GCATCTGCAATGGATGGT-3¢, antisense primer: 5¢-
TGTTCTTGCGGATCATGTGT-3¢. The amplification
program consisted of 1 cycle at 95C for 10 min fol-
lowed by 40 cycles with a denaturing phase at 95C for
30 s, an annealing phase at 60C for 1 min, and an
elongation phase at 72C for 1 min. PCR products
were analyzed on an ethidium bromide stained 1%
agarose gel, and a melting curve analysis was per-
formed after amplification to verify the accuracy of
the amplicon. In each real-time PCR run for F3 and
L28, a calibration curve was included that was gen-
erated from serial dilutions of the respective purified
amplicon [24, 27].
j TF activity
Tissue factor activity was analyzed at the surface of
HAEC and in mouse carotid artery tissue homoge-
nates, respectively, using a colorimetric assay
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(American Diagnostica) according to the manufac-
turer’s recommendations with some modifications as
described [5]. Right carotid arteries were homoge-
nized in 50 ll of lysis buffer (50 mmol Tris–HCl,
100 mmol NaCl, 0.1% Triton X-100 pH 7.4) 5 h after
oral gavage of guggulsterone (100 mg/kg) or vehicle
(0.5% methyl cellulose, 10 ml/kg) and left to stand on
ice for 30 min. TF/FVIIa converted factor X to factor
Xa, which was measured by its ability to metabolize a
chromogenic substrate. A standard curve with lipi-
dated human TF was performed to assure that mea-
surements were taken in the linear range of detection.
j Carotid artery thrombosis model
Sixteen weeks old C57BL/6 mice weighing on average
28 ± 1 g were anesthetized by intraperitoneal injec-
tion of 2.4 mg sodium pentobarbital (Butler, Colum-
bus, OH) as described [5]. Rose bengal (Fisher
Scientific, Fair Lawn, NJ) was diluted to 12 mg/ml in
phosphate-buffered saline and then injected into the
tail vein at a dose of 50 mg/kg. Mice were secured in a
supine position, placed under a dissecting microscope
(Olympus C-4040 Zoom), and the right common car-
otid artery was exposed following a midline cervical
incision. A Doppler flow probe (Model 0.5 VB, Tran-
sonic Systems, Ithaca, NY) was applied and connected
to a flowmeter (Transonic, Model T106). After 6 min
of rose bengal injection, a 1.5-mW green light laser
(540 nm; Melles Griot, Carlsbad, CA) was applied to
the site of injury at a distance of 6 cm for 60 min or
until thrombosis occurred. From the onset of injury,
blood flow was monitored for 120 min, at which time
the experiment was terminated. Occlusion was defined
as flow £0.1 ml/min for at least 1 min [8]. Mice were
divided into two groups: guggulsterone (oral gavage,
5 h before surgery; 100 mg/kg guggulsterone diluted
in 0.5% methyl cellulose in an injection volume of
10 ml/kg), or vehicle control (0.5 % methyl cellulose).
j Statistics
Data are presented as mean ± SEM. Statistical anal-
ysis was performed by 2-tailed unpaired Student’s t
test or ANOVA as appropriate. A probability value
of <0.05 was considered significant.
Results
j Guggulsterone inhibits TNF-a-induced TF protein
expression and activity in vascular cells
Human aortic endothelial cells were stimulated with
TNF-a (5 ng/ml) for 5 h in the presence or absence of
guggulsterone. Guggulsterone inhibited TNF-a-in-
duced TF expression in a concentration-dependent
manner with a maximal effect occurring at 10)4 mol/l
(n = 7; P < 0.05; Fig. 1a); similarly, it impaired TNF-
a-induced TF surface activity (n = 4; P < 0.05; Fig. 1
b). Guggulsterone also inhibited TF expression in
VSMCs (n = 4; P < 0.05; Fig. 1c), but not in THP-1
cells (n = 5; P = NS; Fig. 1d). In contrast to gugguls-
terone, dexamethasone did not affect TNF-a-induced
TF expression (n = 6; P = NS; data not shown).
j Guggulsterone enhances endothelial TFPI and
inhibits PAI-1 as well as VCAM-1 expression
Guggulsterone enhanced basal expression of TFPI in a
concentration-dependent manner (n = 3; P < 0.05;
Fig. 2a), but did not affect TNF-a-induced TFPI
expression (n = 3; P = NS; Fig. 2a). Guggulsterone
inhibited basal expression of PAI-1 in a concentra-
tion-dependent manner (n = 7; P < 0.05; Fig. 2b),
and a similar effect was observed after TNF-a stimu-
lation (n = 7; P < 0.05; Fig. 2b). Moreover, gugguls-
terone inhibited TNF-a-induced VCAM-1 expression
in a concentration-dependent and potent manner
(n = 7; P < 0.05; Fig. 2c). In contrast to guggulster-
one, dexamethasone only weakly impaired TNF-a-
induced VCAM-1 expression (15% inhibition; n = 3;
P < 0.05; data not shown).
j Guggulsterone is not toxic for vascular cells
Human aortic endothelial cells and VSMCs were
treated with increasing concentrations of guggulster-
one or dexamethasone for 6 h. Morphological exam-
ination of the cells did not reveal any changes (n = 4–
14; data not shown). Moreover, no signs of toxicity
were detected by LDH release (n = 4–14; P = NS; data
not shown).
j Guggulsterone inhibits endothelial TF mRNA
expression
Real-time PCR revealed that TF mRNA expression
was induced after 2 h of TNF-a stimulation (n = 4;
P < 0.05; Fig. 3). Guggulsterone inhibited TNF-a-in-
duced TF mRNA expression in a concentration-
dependent manner (n = 4; P < 0.05; Fig. 3).
j Guggulsterone impairs endothelial TF expression
via MAP kinase inhibition
The MAP kinases JNK, p38 and ERK were transiently
activated by TNF-a (n = 5; Fig. 4a). Guggulsterone
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inhibited phosphorylation of JNK and p38, while
that of ERK remained unaffected (n = 5; Fig. 4a, b).
No significant change in total expression of MAP
kinases was observed at any time point with or
without guggulsterone. To verify the involvement of
MAP kinases in TNF-a-induced TF expression, the
TF
GAPDH
TNF-α
(5 ng/ml) ++++++––
++––
4–4–
++––
4–4–
++++++––
45678–4–
45678–4
A B
C D
–
Guggulsterone
(-log mol/l)
TF
 E
xp
re
ss
io
n 
H
AE
C 
(%
)
TF
 A
ct
iv
ity
 H
AE
C 
(%
)
TNF-α
(5 ng/ml)
Guggulsterone
(-log mol/l)
TF
GAPDH
TNF-α
(5 ng/ml)
Guggulsterone
(-log mol/l)
TF
GAPDH
TNF-α
(5 ng/ml)
Guggulsterone
(-log mol/l)
0
25
50
75
100
125
*
TF
 E
xp
re
ss
io
n 
VS
M
C 
(%
)
0
50
100
150
TF
 E
xp
re
ss
io
n 
TH
P-
1 
 (%
)
0
25
50
75
100
125
*
*
0
25
50
75
100
125
*
*
Fig. 1 Guggulsterone inhibits TF protein expression and activity. a Gugguls-
terone inhibits TNF-a-induced TF protein expression of human aortic
endothelial cells (HAECs) (P < 0.05 vs. TNF-a alone). b Guggulsterone inhibits
TNF-a-induced TF surface activity of HAECs (P < 0.05 vs. TNF-a alone). c
Guggulsterone inhibits TNF-a-induced TF protein expression of human aortic
vascular smooth muscle cells (P < 0.05 vs. TNF-a alone). d Guggulsterone does
not affect TNF-a-induced TF protein expression of THP-I cells (P = NS vs. TNF-
a alone). Values are indicated as percent of TNF-a alone; all blots are
normalized to GAPDH expression
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action of MAP kinase inhibitors was examined.
PD98059, SP600125, and SB203580, which specifically
inhibit ERK, JNK, and p38, respectively, significantly
impaired TF expression after TNF-a stimulation
(n = 6; P < 0.05 for TNF-a alone versus each
inhibitor; Fig. 4c).
j Farnesoid X receptor (FXR) does not mediate the
effect of guggulsterone
Human aortic endothelial cells were stimulated with
TNF-a (5 ng/ml) for 5 h after a 1-h treatment with
guggulsterone (10)4 M) or GW-4064 (10)5 M), a
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Fig. 2 Guggulsterone enhances endothelial TFPI and impairs PAI-1 as well as
VCAM-1 expression. a Guggulsterone enhances basal TFPI expression (P < 0.05
vs. control), but does not affect TNF-a-induced TFPI expression (P = NS vs.
TNF-a alone). b Guggulsterone inhibits basal PAI-1 expression (P < 0.05 vs.
control), and a similar effect is observed after TNF-a stimulation (P < 0.05 vs.
TNF-a alone). c Guggulsterone inhibits TNF-a-induced VCAM-1 expression
(P < 0.05 vs. control). Values are indicated as percent of control or TNF-a
alone; all blots are normalized to GAPDH expression
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selective and potent FXR agonist. Guggulsterone and
GW-4064 both decreased TNF-a-induced endothelial
TF protein expression with similar potency (n = 4;
*P < 0.05). The effect of guggulsterone remained
unaltered following treatment with the FXR agonist
GW-4064 (n = 4; P = NS). No cytotoxic effect of ei-
ther substance was observed as measured by LDH
release (data not shown).
j Guggulsterone inhibits TF activity and arterial
thrombosis in vivo
Treatment with guggulsterone (100 mg/kg) impaired
TF activity in mouse carotid artery in vivo (n ‡ 4;
P < 0.05 for guggulsterone vs. vehicle; Fig. 5a). Pho-
tochemical injury is an established model of TF
depending arterial thrombosis [4]. Initial blood flow
in carotid artery of vehicle-treated mice equalled
0.58 ± 0.03 ml/min (n = 4); these mice developed
thrombotic occlusion within a mean occlusion time of
36.06 ± 2.12 min (n = 4; Fig. 5b). Guggulsterone-
treated mice exhibited similar initial blood flow
(0.67 ± 0.09 ml/min; n = 7; P = NS for guggulsterone
vs. vehicle), but developed thrombosis within a mean
occlusion time of 55.51 ± 4.83 min (n = 7; P < 0.05
for guggulsterone vs. vehicle; Fig. 5b).
j Guggulsterone inhibits proliferation and migration
of human VSMCs
Guggulsterone inhibited VSMC proliferation in re-
sponse to 10% FCS in a concentration-dependent
manner by 82% at the maximal concentration
(n = 11; P < 0.05; Fig. 6a). Likewise, guggulsterone
inhibited VSMC migration in response to 10 ng/ml
platelet-derived growth factor-BB in a concentration-
dependent manner by 99% at the maximal concen-
tration (n = 5; P < 0.05; Fig. 6a).
Discussion
This study demonstrates that the anti-inflammatory
phytosterol guggulsterone inhibits TF in HAECs and
VSMCs; this effect is related to impaired activation of
the MAP kinases JNK and p38 in endothelial cells,
resulting in a diminished level of TF mRNA, protein,
and activity. Consistent with these observations,
guggulsterone inhibits TF activity as well as throm-
botic occlusion of mouse carotid artery in vivo.
Moreover, guggulsterone impairs proliferation and
migration of vascular smooth muscle cells. Hence,
guggulsterone may be considered as a novel anti-
thrombotic agent for treating inflammatory vascular
disorders.
Chronic systemic inflammation, as encountered in
rheumatoid arthritis or systemic lupus erythema-
todes, is associated with a considerably increased risk
of cardiovascular disease [13, 35]. TF plays a crucial
role in inflammation-induced coagulation as it is
upregulated in vascular cells and in vivo by several
inflammatory mediators [16, 28, 32]. As a conse-
quence, recent efforts have focused on novel strategies
for targeting TF. The phytosterol guggulsterone seems
to be a suitable candidate, as it exhibits potent anti-
inflammatory and anti-thrombotic properties.
Significant impairment of TF expression in vitro
occurred at concentrations as low as 10 lM. Up to
now, the pharmacokinetics of guggulsterone in hu-
mans remain unknown; however, clinical trials per-
formed in humans indicate that doses up to 6 g per
day are safe and well tolerated [29]. This dose cor-
relates well to that applied in our mouse experiments
(100 mg/kg bodyweight). A study performed in rats
revealed that 50 mg/kg bodyweight oral application of
guggulsterone resulted in peak plasma concentrations
of 3.2 lM [36]. In view of the above, the guggulster-
one concentrations applied in vitro may reasonably
well match the plasma concentrations reached in our
in vivo experiments.
Activation of MAP kinases mediates TF expression
in response to many stimuli [18, 25, 28, 30]. Gug-
gulsterone impaired endothelial TF expression by
specifically decreasing phosphorylation of JNK and
p38, but not ERK, and consistent with MAP kinase
inhibition, guggulsterone promoted a strong reduc-
tion in TNF-a-induced TF mRNA. Hence, in endo-
thelial cells, the inhibitory effect of guggulsterone is
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Fig. 3 Guggulsterone inhibits endothelial TF mRNA expression. Real-time PCR
reveals that guggulsterone inhibits TNF-a-induced TF mRNA expression
(P < 0.05 vs. TNF-a alone). Values are indicated as percent of TNF-a alone and
normalized to L28 expression
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related to MAP kinase inhibition and occurs at the
transcriptional level. Since TNF-a regulates TF
expression in vascular smooth muscle cells via acti-
vation of MAP kinases as well, its inhibitory effect in
this cell type may be similar to that in endothelial
cells. This profile of action is remarkably similar to
that of dimethylsulfoxide, another inhibitor of TF
expression proposed for application on drug-eluting
stents [5].
Guggulsterone is an antagonist of the FXR, a key
regulator of cholesterol homeostasis [33]. Recent
studies demonstrate that FXR is expressed and func-
tional in vascular endothelial cells indicating that FXR
may play a role in endothelial homeostasis and serve
as a novel molecular target for manipulating vascular
inflammation [4, 11, 17]. FXR is activated by bile
acids such as chenodeoxycholic acid (CDCA); in
addition, synthetic FXR agonists such as GW4064
have been developed. Both guggulsterone and GW-
4064 decreased TNF-a-induced endothelial TF
expression with similar potency; moreover, the effect
of guggulsterone on endothelial TF expression re-
mained unaltered in the presence of GW-4064. These
observations suggest that the antithrombotic effects of
guggulsterone occur independent of FXR inhibition.
Tissue factor activity is counterbalanced by its
endogenous inhibitor TFPI, which is mainly produced
by endothelial cells; the balance of these two factors is
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Fig. 4 Guggulsterone impairs
endothelial TF expression via MAP
kinase inhibition. a The MAP kinases
JNK, p38, and ERK are transiently
activated by TNF-a (5 ng/ml).
Guggulsterone inhibits phosphorylation
of JNK and p38, but not ERK. No
significant change in total expression of
MAP kinases is observed. b Inhibition of
MAP kinase activation by guggulsterone
(P < 0.05 vs. TNF-a alone). c PD98059,
SB203580, and SP600125, specifically
inhibiting ERK, p38, and JNK,
respectively, impair TF expression after
TNF-a stimulation (P < 0.05 for TNF-a
alone vs. each inhibitor)
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indeed essential in determining thrombus formation
[6]. Guggulsterone enhanced basal TFPI expression,
which underlines the anti-thrombotic properties of
this drug. However, TFPI release remained unaltered
in TNF-a stimulated cells, indicating that the effect of
guggulsterone on TFPI expression depends on the
activation status of the cells. Hence, in an inflamma-
tory environment, the effect of guggulsterone on TFPI
expression appears to be overcome by the pro-
thrombotic action of inflammatory mediators. How-
ever, under these circumstances, guggulsterone
inhibited TF expression, and the lower TF expression
in cytokine stimulated cells was not counteracted by a
parallel decrease in TFPI; therefore, guggulsterone
would be expected to exert potent antithrombotic
actions even in an inflammatory environment by
reducing TF instead of enhancing TFPI expression.
PAI-1 is a serpin suppressing fibrinolysis by inhibit-
ing the activity of tissue plasminogen activator (tPA).
PAI-1 levels are elevated in patients with diabetes
mellitus and coronary artery disease [2, 21] and are
associated with an enhanced risk of coronary events
[10, 12]. Besides its effects on TF and TFPI, gugguls-
terone downregulated PAI-1 expression both in qui-
escent and TNF-a stimulated cells; hence,
guggulsterone may be particularly beneficial in pa-
tients with diabetes mellitus.
Photochemical injury was selected for examining
thrombus formation because it is an established
protocol for TF-dependent arterial thrombosis in vivo
[5, 7, 8]. Guggulsterone inhibited thrombotic occlu-
sion, indicating that it may protect from thrombus
formation. Indeed, inhibition of TF activity in the
mouse carotid artery within 5 h of guggulsterone
administration was confirmed and is the most likely
explanation for the effect of guggulsterone on
thrombus formation.
Migration and proliferation of VSMCs are crucial
events involved in neointima formation and resteno-
sis after percutaneous revascularisation. Hence, sub-
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Fig. 6 Guggulsterone inhibits vascular smooth muscle cell activation. a
Guggulsterone inhibits vascular smooth muscle (VSMC) proliferation (n = 11;
P < 0.05 vs. control). b Guggulsterone inhibits vascular smooth muscle (VSMC)
migration (n = 5; P < 0.05 vs. control)
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stances are applied on drug-eluting stents to reduce
restenosis through inhibition of VSMC activation.
This study demonstrates that guggulsterone effec-
tively inhibits VSMC proliferation and migration. In
addition to VSMC, TF has been implicated in the
pathogenesis of neointima formation and stent
thrombosis [20, 24, 27]. The pronounced inhibition of
both VSMC activation and TF expression renders
guggulsterone an attractive candidate for application
on drug-eluting stents.
In summary, this study demonstrates that gug-
gulsterone impairs TF in vascular cells and prevents
thrombotic occlusion in vivo; further, guggulsterone
inhibits VSMC proliferation and migration. These
findings may offer new therapeutic approaches to
prevent thrombosis in chronic inflammatory disor-
ders or in the context of drug-eluting stents. The
known ability of guggulsterone to inhibit platelet
aggregation may indeed be very important in this
regard [9]. However, further in vivo studies are nee-
ded to assess potential therapeutic effects of gug-
gulsterone on neointima formation. Moreover,
additional studies need to clarify whether gugguls-
terone’s effects are modulated by differences in ge-
netic background, lifestyle or diet [29]. Only then can
specific applications of guggulsterone for the treat-
ment of vascular disease be developed and tested in
humans.
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